Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIUM GLUCEPTATE vs MICRO-K LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.
Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.
Treatment of hypocalcemia,Calcium supplementation in patients requiring parenteral calcium,Treatment of hypermagnesemia,Cardiac resuscitation (as an adjunct),Treatment of calcium channel blocker overdose
Hypokalemia prevention or treatment,Diuretic-induced hypokalemia,Digitalis intoxication
IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.
10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.
Terminal elimination half-life: 2-4 hours (normal renal function); prolonged to 12-24 hours in renal impairment.
Not applicable (K+ is an electrolyte, not eliminated by first-order kinetics). Clinical context: Serum K+ decline follows redistribution and excretion with a half-life of ~2-4 hours after IV bolus.
Calcium gluceptate is not metabolized; it dissociates into calcium ions and gluceptate. Calcium ions are excreted primarily in feces and urine, with renal handling involving reabsorption and secretion.
Not metabolized; excreted primarily via kidneys.
Renal: >90% excreted unchanged in urine. Biliary/fecal: <5%.
Renal: ~90% as KCl (proportional to intake). Biliary/fecal: <10%.
~45% bound to albumin.
None (K+ is free ion).
0.15-0.25 L/kg; represents distribution mainly in extracellular fluid.
0.35 L/kg (approximate total body water; distributes primarily in extracellular fluid).
IV: 100%; IM: not well characterized; oral: negligible (absorbed poorly, systemic bioavailability <1% as calcium gluceptate dissociates in GI tract).
Oral: ~80-100% for microencapsulated KCl (MICRO-K), but can be incomplete due to slower release.
GFR >50: No adjustment. GFR 30-50: Reduce dose by 25%. GFR <30: Reduce dose by 50% and monitor serum calcium closely. Dialysis: Dose after hemodialysis.
GFR 50-90 m L/min: no adjustment. GFR 30-49 m L/min: reduce dose by 25-50%. GFR <30 m L/min: avoid use or reduce dose by 50-75% with close monitoring.
No dose adjustment required for hepatic impairment. However, monitor ionized calcium in severe hepatic failure due to altered binding proteins.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: avoid use or reduce dose by 50%.
Neonates and infants: 100-200 mg elemental calcium/kg/day IV divided every 6 hours. Children: 200-500 mg elemental calcium/kg/day IV divided every 6 hours. Maximum: 1 g elemental calcium per dose.
1-3 m Eq/kg/day orally in 2-4 divided doses; maximum 1 m Eq/kg per dose and 100 m Eq/day.
Use lower initial doses (e.g., 1-2 mg/kg elemental calcium) due to reduced renal function and increased risk of hypercalcemia. Monitor serum calcium and phosphate levels.
Initiate at lower end of dosing range (10-20 m Eq/day); monitor renal function and serum potassium frequently; adjust based on renal function.
No FDA black box warning.
No black box warning.
Risk of hypercalcemia, especially in patients with renal impairment,Avoid rapid intravenous administration to prevent cardiac arrest,Use with caution in patients with sarcoidosis or digitalis toxicity,Monitor serum calcium levels during therapy,Extravasation may cause tissue necrosis
Risk of hyperkalemia especially in renal impairment,Use with caution in cardiac disease,GI irritation or ulceration with oral forms,Slow release formulations may cause GI lesions
Hypercalcemia,Hypersensitivity to calcium gluceptate or any component,Ventricular fibrillation,Patients with known calcium-containing calculi
Hyperkalemia,Severe renal impairment,Untreated Addison's disease,Acute dehydration,Use of potassium-sparing diuretics
Avoid high-calcium foods (dairy, fortified cereals) during acute therapy to prevent hypercalcemia. Limit vitamin D-rich foods (fatty fish, fortified milk). Do not take oral calcium within 1 hour of iron or thyroid medications. Avoid excessive caffeine and alcohol.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados, dried fruits, salt substitutes containing potassium chloride). Do not take with alcohol as it may increase GI irritation. Grapefruit juice has no significant interaction, but large amounts of any food high in potassium should be avoided.
Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No increased risk of major malformations. Second and third trimesters: Adequate intake supports fetal skeletal mineralization; excess may cause hypercalcemia in the infant. No known teratogenicity.
MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.
Calcium gluceptate is considered safe during breastfeeding. Calcium is naturally present in breast milk; supplementation does not significantly alter milk calcium levels. M/P ratio not established, but endogenous calcium transport suggests minimal risk. Use with caution in mothers with hypercalcemia.
Potassium is a normal component of breast milk. No adverse effects expected at maternal therapeutic doses. M/P ratio: not applicable (endogenous electrolyte).
No specific dose adjustment required in pregnancy; maintain recommended daily intake (1000-1300 mg elemental calcium). Pharmacokinetic changes in pregnancy (increased absorption, renal clearance) may slightly alter requirements, but standard doses are safe. Intravenous use should be adjusted based on serum calcium monitoring.
No dose adjustment typically required. Maintain serum potassium within normal range. Monitor for hypokalemia or hyperkalemia as clinically indicated.
Calcium gluceptate is used for acute hypocalcemia, hyperkalemia cardiotoxicity, and hypermagnesemia. Administer IV slowly (0.5-1 m L/min) to avoid arrhythmias; monitor ECG during infusion. Do not mix with bicarbonate, phosphate, or sulfate-containing solutions. Extravasation causes tissue necrosis; use central line for peripheral therapy. Correct hypomagnesemia before calcium therapy to prevent refractory hypocalcemia.
MICRO-K LS contains potassium chloride microencapsulated granules for sustained release. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min), untreated Addison's disease, or hyperkalemia. Use with caution in patients with cardiac disease or concurrent use of ACE inhibitors, ARBs, or potassium-sparing diuretics. Do not crush or chew capsules; administer with a full glass of water to prevent GI mucosal damage. Monitor serum potassium regularly, especially in elderly and diabetic patients.
Report any burning or pain at injection site immediately.,Avoid taking calcium supplements or antacids without consulting your doctor.,Tell your doctor if you have kidney stones, parathyroid disorders, or heart disease.,Do not stop other calcium medications abruptly.,Seek emergency care for difficulty breathing or chest tightness after infusion.
Take this medication exactly as prescribed, preferably with meals or a full glass of water.,Do not crush, chew, or break the capsules; swallow them whole.,Avoid foods high in potassium (e.g., bananas, oranges, tomatoes, salt substitutes) unless directed by your doctor.,Contact your doctor immediately if you experience muscle weakness, irregular heartbeat, numbness/tingling, or dark/tarry stools.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIUM GLUCEPTATE vs MICRO-K LS, answered by our medical review team.
CALCIUM GLUCEPTATE is a Electrolyte Supplement that works by Calcium gluceptate is a calcium salt that dissociates to provide calcium ions, which are essential for various physiological processes including nerve conduction, muscle contraction, blood coagulation, and cardiac function. It acts as a calcium replenisher.. MICRO-K LS is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIUM GLUCEPTATE and MICRO-K LS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIUM GLUCEPTATE is: IV: 2-4 mg/kg elemental calcium (5-10 m L of 0.45 m Eq/m L solution) administered slowly over 10-20 minutes. May repeat if needed. Maximum dose: 20 m L per infusion.. The standard adult dose of MICRO-K LS is: 10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIUM GLUCEPTATE and MICRO-K LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIUM GLUCEPTATE is classified as Category C. Calcium gluceptate is a calcium salt used for calcium supplementation. No specific teratogenic effects are reported; calcium is essential for fetal development. First trimester: No. MICRO-K LS is classified as Category C. MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.